

29 October 2015
EMA/706557/2015
Corporate Stakeholders Department

Report of meeting held with Lif – the Danish Association of the Pharmaceutical Industry

30 September 2015, at the EMA

Participants:

EMA: M. Carr (Chair), M-H. Pinheiro, A. Szmigiel, E. Tognana, M-A. Heine (for part of meeting)

Lif: H. Vestergaard, A. Skårup Kristensen, C. Blæsberg, J. Larsen, S. Beicker Sørensen, T. Klit Christensen, J. Clausen, M. Møller Rasmussen, L. Bech, L. Laier-Brodersen, L. Katharina Volke, L. Remmer Nürnberg, L. Broe

Objectives of the meeting:

- To provide a general introduction for Lif on the role and responsibilities of the EMA.
- To enhance EMA understanding of this national trade association (& member of EFPIA, AESGP and IFPMA), its activities and key areas of interest.

Topics addressed with agreed actions, if any:

- A general introduction to the EMA and the European Medicines Regulatory Network was provided, together with more detailed presentations on the centralised procedure for marketing authorisation and pharmacovigilance activities.
- An introduction to the Danish Association of Pharmaceutical Industry (Lif) was presented. Lif represents the R&D-based pharmaceutical industry in Denmark, with 33 member companies. The association has 3 political committees focussing on Research and Innovation Policy, Healthcare and Industrial Policy and Communication Policy, as well as a number of expert committees in specific areas such as vaccines and pharmacovigilance.
- Discussion focussed on the support EMA provides to development through scientific advice, biosimilar medicines, increasingly globalised development and manufacturing, the impact of new pharmacovigilance legislation, patient involvement in EMA activities, and IMI projects.

Action: EMA to provide links to further information on the IMI WEB-RADR and Get-Real projects.